Recherches & Rapports

Gwangdong Pharmaceutical has been chosen for the Korea Environment Corporation’s 2026 Smart Eco‑Factory project, aiming to install energy‑saving boilers, waste‑heat recovery and other low‑carbon equipment.

Daewoong Pharmaceutical reports that its SGLT‑2 inhibitor Enblo improved metabolic‑associated fatty liver disease in type‑2 diabetes patients, per a study in the journal Diabetes, Obesity and Metabolism.

A large analysis of 21 randomized controlled trials suggests that artificial sweeteners could worsen blood‑sugar control, raising HbA1c and insulin levels.

A 25‑year Danish‑led study of 3 million women found increased meningioma risk with certain combined oral contraceptives and high‑dose hormonal IUDs, extending prior concerns about high‑dose progestins.

LIGACEM BioScience announced its LCB 2.0 R&D roadmap at Global R&D Day 2026, aiming to boost ADC innovation, expand into next‑generation modalities and accelerate high‑value technology transfer.

OraFang, an oral tablet bowel preparation, demonstrated safety similar to standard 2L PEG solution in a real-world analysis of 16,709 colonoscopy patients, including the very elderly and those with organ dysfunction.

LigaChem Bio presented its 2035 R&D roadmap, aiming to enhance its ADC platform, explore non‑oncology indications and boost next‑generation drug success through patient‑centric research.

MetaCentra Therapeutics teams up with Samsung Health to provide users with an Advanced Glycation End‑Products (AGE) index and related health‑management content within the app.

Novo Nordisk has teamed up with US‑based Vivani Medical to create NPM‑139, a small semaglutide implant aimed at chronic weight management, diversifying its GLP‑1 delivery options.

Boehringer Ingelheim has secured exclusive rights to PVT’s Orf virus (ORFV) platform for cancer vaccine development, while PVT retains rights for other indications.

A recent note says most of the two‑week deviation investigation time is spent on data collection, not science, highlighting a bottleneck for AI tools in pharma.

LG Chem announced a partnership with UK AI drug‑development firm LabGenius Therapeutics to jointly discover multi‑antibody cancer drug candidates using AI and automated experiments.